Ventyx Biosciences (VTYX) Reports Q3 Results, Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update
November 17, 2021 4:11 PM ESTWholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets
Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor
Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3Â million in gross proceeds, including full exercise of underwriters option to purchase additional shares
ENCINITAS, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq:... More
